Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia

Sponsor
Nantes University Hospital
Study ID
NCT07099443
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Non-Interventional Sample Collection and Analysis — OTHER
    This study is observational. Biological samples are collected as part of standard care or for research purposes and analyzed to characterize resistance mechanisms. No treatment or intervention is administered as part of the study protocol.

Study Details

The aim of the REBELLE cohort - bio-collection is to collect samples from patients with Chronic Lymphocytic Leukemia candidates or those exposed to BTK degraders to evaluate the mechanisms of resistance to these new molecules. To do this, an additional blood or bone marrow sample to those planned in the context of patient care or a residual lymph node biopsy sample will be collected after signing consent.

Key Dates

First listed
Aug 1, 2025
Start date
Oct 9, 2025
Status verified
Apr 2026
Primary completion
Sep 15, 2039
Completion
Sep 15, 2039

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Chronic Lymphocytic Leukemia candidates or those exposed to BTKd
    Collection of additional samples of blood and bone marrow or residual lymph node biopsy at the time of inclusion (for diagnosis or relapse), month 6 and relapse.

Primary Outcome Measure

Characterization of resistance mechanisms to CLL patients candidates or exposed to BTKd. [ Time Frame: Up to 5 years after inclusion ]

Central Contacts

Find similar trials

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials

Related Studies